Myungjeon Bio — Bioecon

Профиль

Myungjeon Bio (Myeongjeon Bio Co., Ltd.) is a South Korean company established in 2012 that specializes in eco-friendly agricultural inputs, primarily focusing on the development and commercialization of water-soluble silicate (SiO₃) technology. Headquartered in Jincheon-gun, Chungcheongbuk-do, the company is led by CEO Lee Yoon-jung and maintains approximately 15 to 16 employees.

The company’s core technology involves processing 99.9% pure natural silica at temperatures exceeding 2,200 degrees Celsius to create highly absorbable silicate products. Its flagship brand, Sista, includes liquid and granular fertilizers designed to improve crop yield, pest resistance, and soil health. These products are used for various crops, including rice, ginseng, and vegetables, and are compatible with drone and aerial spraying.

Myungjeon Bio is an active, ongoing business. It exports to countries including China, Japan, Laos, and Vietnam, and is currently researching applications for its silicate technology in the food and medical sectors. The company holds various certifications, including ISO 9001 and 14001, and has secured multiple patents for its proprietary manufacturing processes.

Sources#

Отрасль: Цифровизация и робототехника, Корма
Темы: Корма и кормовые добавки
Роль: Производитель — “…patents for its proprietary manufacturing processes [1]. ### Sources - [[인터뷰] 명전바이오, ‘수용성 규산염’으로 친환경농업 새 지평 연다…”

Биорешения, которые поставляет 0

Пока не указана поставщиком в решениях с доказательствами.

Что предлагают

Компания не публикует продукты и услуги — узнаем через знакомство.

Новости и статус 6

2026-04-01 Woojeong Bio announced on the 1st that it has appointed Moon Byung-seok, head of Kolmar Holdings Tec.. - MK
Woojeong Bio (not Myungjeon Bio) announced that Moon Byung-seok, former head of Kolmar Holdings Technology Research Institute, has been appointed as the new CEO to strengthen R&D, open innovation, and convergence bio-business across pharmaceuticals, health …
2026-05-27 While the domestic bio industry is experiencing a long recession, it has been pointed out that in or.. - MK
Moonjeong Bio (Kim Moonjeong) is discussed as a focal point in calling for policy change to break away from a supplier-centered approach and toward a market/customer-centered ecosystem. The emphasis is on reducing inter-ministerial inefficiencies, accelerating …
2026-03-04 Woojeong Bio, which switched to a second-generation management system after the death of its founder.. - MK
Myungjeon Bio is not mentioned in the provided article. The piece discusses Woojeong Bio’s plan to issue 35 billion won in convertible bonds to Kolmar Holdings, which would make Kolmar the largest shareholder and lead to a second-generation management …
2026-09-28 Jinjeon Biopharmaceuticals will start a new production line in October that can supply products wort.. - MK
Jinjeon Biopharmaceuticals (not Myungjeon Bio) announced it will start a new automated production line in October, investing about 1 billion won to supply 5–7 billion won per year to global retailers, boosting annual earnings and diversifying from its …
2026-09-16 NgeneBio draws 7,374% demand, secures 7.7 billion won in South Korea offering - CHOSUNBIZ
Summary: The article highlights NgeneBio’s strong investor demand in Korea, securing 7.7 billion won from its offering, which implies positive momentum for the broader Korean biotech sector that includes companies like Myungjeon Bio.
2026-09-11 Ujeong Bio Becomes Kolmar Biotech, Spearheading Kolmar Group’s Biotech Strategy
Kolmar Biotech, formerly Ujeong Bio, is expanding beyond preclinical support into raw-material development and manufacturing, branding its model as a “Bio Research Foundry” to bolster private-sector biotech infrastructure in Korea. There’s no mention of …

Связи: владельцы, партнёры, аналоги

Реквизиты и контакты

Контакты, руководители и юридические данные доступны участникам.

Войти как участник